Gonadal failure following busulfan therapy in an adolescent girl.

Abstract

A girl with Philadelphia chromosome-positive CML (Ph1-positive CML) was treated with busulfan from the age of 10 years 11 months to 16 years. Before treatment she had no evidence of pubertal development and no sexual development has occurred over the ensuing 5 years. Endocrine evaluation revealed that the child had ovarian failure. The pubescent female appears to be prone to develop gonadal failure with resultant lack of sexual development when treated with busulfan during this period in her life.

• Authors: B López-Ibor, A D Schwartz
• Journal: The American journal of pediatric hematology/oncology (Am J Pediatr Hematol Oncol) Vol. 8 Issue 1 Pg. 85-7 ( 1986) ISSN: 0192-8562 [Print] United States
• PMID: 3459380 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Cyclophosphamide
• Busulfan

Topics

• Adolescent
• Busulfan (adverse effects)
• Cyclophosphamide (adverse effects)
• Female
• Humans
• Leukemia, Myeloid (drug therapy)
• Ovarian Diseases (chemically induced)
• Ovary (drug effects)
• Puberty
• Sexual Maturation (drug effects)